Home » Newsletters » BioWorld Science

BioWorld Science

July 12, 2017

View Archived Issues

MAX BioPharma obtains proof-of-concept data on Oxy-200 for osteoporosis

GeoVax's LASV vaccine candidate shows efficacy in animal model

FDA awards orphan drug status to Principia Biopharma's PRN-1008

Regulatory update for tucatinib in Europe

Unity Biotechnology patents Bcl-W, Bcl-XL and Bcl-2 inhibitors

Merck & Co. discloses Nav1.7 blockers

Bristol-Myers Squibb divulges apelin receptor agonists

Gilead Sciences patents TBK1 and IKK-E kinase inhibitors

Novartis presents guanylate cyclase activators

FDA issues complete response letter regarding Dextenza NDA

ViraCyte completes phase I study of Viralym-C

Nektar Therapeutics describes activity of autoimmune disease candidate NKTR-358

Daiichi Sankyo enters cancer reseach agreement with Max Planck and Lead Discovery Center

First-in-human results for inactivated influenza vaccine delivered by microneedle patch

First patient dosed in phase I study of ARQ-531

Novel TER ATPase inhibitor OSSL-325096 developed for treating multiple myeloma

CURE Pharmaceutical, Therapix to enter research collaboration with Assuta Medical Centers

MedigenixBio tests new antithrombotic compound MDI-2001 in vivo

FDA advisory committee votes in favor of Mylotarg for newly diagnosed AML

Amicus plans migalastat NDA for Fabry disease based on FDA communications

Xadago launched in U.S.

FDA grants full approval to Blincyto for B-cell precursor ALL

First-in-human study finds TFPI inhibitor PF-06741086 well tolerated

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.